Q2 Earnings Forecast for UNCY Issued By Noble Financial

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at Noble Financial issued their Q2 2025 earnings estimates for shares of Unicycive Therapeutics in a note issued to investors on Thursday, May 15th. Noble Financial analyst R. Leboyer expects that the company will earn ($0.07) per share for the quarter. The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($0.23) per share. Noble Financial also issued estimates for Unicycive Therapeutics' Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.13 EPS and FY2025 earnings at $0.04 EPS.

UNCY has been the subject of several other research reports. HC Wainwright restated a "buy" rating and set a $7.50 price target on shares of Unicycive Therapeutics in a research report on Friday, April 11th. Guggenheim started coverage on shares of Unicycive Therapeutics in a research report on Monday, April 21st. They set a "buy" rating and a $6.00 target price for the company.

Unicycive Therapeutics Stock Performance

UNCY opened at $0.60 on Monday. The firm has a market cap of $71.88 million, a P/E ratio of -0.61 and a beta of 2.14. The firm has a 50-day moving average of $0.59 and a 200 day moving average of $0.61. Unicycive Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $1.08.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.09.

Hedge Funds Weigh In On Unicycive Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Northern Trust Corp boosted its position in Unicycive Therapeutics by 142.4% during the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company's stock worth $46,000 after purchasing an additional 34,183 shares during the period. XTX Topco Ltd lifted its holdings in shares of Unicycive Therapeutics by 142.2% in the fourth quarter. XTX Topco Ltd now owns 171,463 shares of the company's stock worth $136,000 after buying an additional 100,679 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Unicycive Therapeutics by 30.3% in the fourth quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock worth $417,000 after buying an additional 122,089 shares in the last quarter. Acuta Capital Partners LLC lifted its holdings in shares of Unicycive Therapeutics by 16.4% in the fourth quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company's stock worth $1,829,000 after buying an additional 323,801 shares in the last quarter. Finally, Vivo Capital LLC lifted its holdings in shares of Unicycive Therapeutics by 14.0% in the first quarter. Vivo Capital LLC now owns 11,370,152 shares of the company's stock worth $6,537,000 after buying an additional 1,400,000 shares in the last quarter. Institutional investors own 40.42% of the company's stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.